Rankings
▼
Calendar
ORGO Q4 2020 Earnings — Organogenesis Holdings Inc. Revenue & Financial Results | Market Cap Arena
ORGO
Organogenesis Holdings Inc.
$355M
Q4 2020 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$107M
+43.1% YoY
Gross Profit
$81M
76.1% margin
Operating Income
$22M
20.4% margin
Net Income
$18M
17.3% margin
EPS (Diluted)
$0.15
QoQ Revenue Growth
+6.0%
Cash Flow
Operating Cash Flow
$26M
Free Cash Flow
$17M
Stock-Based Comp.
$497,000
Balance Sheet
Total Assets
$290M
Total Liabilities
$148M
Stockholders' Equity
$142M
Cash & Equivalents
$84M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$107M
$75M
+43.1%
Gross Profit
$81M
$54M
+49.8%
Operating Income
$22M
-$2M
+1341.2%
Net Income
$18M
-$4M
+520.5%
Revenue Segments
Advanced Wound care
$94M
88%
Surgical and Sports Medicine
$13M
12%
← FY 2020
All Quarters
Q1 2021 →